Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0086543 (
cataract
)
29,165
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
The effects of vanadyl sulfate treatment on susceptibility to oxidative stress were investigated in streptozotocin-diabetic Wistar rats. A 2 x 2 factorial design was employed, with four groups of animals: 1) untreated, non-diabetic; 2) vanadyl-treated, non-diabetic; 3) untreated, diabetic; and 4) vanadyl-treated, diabetic. Vanadyl sulfate was administered as a 1.00 to 1.25 mg/ml solution in drinking water.
Cataract
development was entirely suppressed in vanadyl-treated compared to untreated, diabetic rats. STZ-induction of diabetes diminished glutathione (GSH) levels in liver homogenates; whereas vanadyl treatment resulted in restored levels of this nonenzymatic antioxidant. Thiobarbituric acid reactive substances (TBARS), both basal and iron-stimulated, were significantly elevated in all vanadyl-treated animals. Vanadyl treatment lowered liver
glutamine synthetase
activities in diabetic rats, but not in non-diabetic animals. Thus, vanadyl treatment was antioxidant in terms of
cataract
formation and reduced glutathione concentration in liver homogenates, pro-oxidant by reason of iron-stimulated TBARS formation and inconclusive with respect to
glutamine synthetase
activity. These results highlight the importance of using multiple indicators of peroxidative change in evaluating new pro-oxidant/antioxidant treatment regimens.
...
PMID:Effect of vanadyl sulfate feeding on susceptibility to peroxidative change in diabetic rats. 810 Jun 38
Loss-of-function mutations in glutaminase (GLS), the enzyme converting glutamine into glutamate, and the counteracting enzyme
glutamine synthetase
(GS) cause disturbed glutamate homeostasis and severe neonatal encephalopathy. We report a de novo Ser482Cys gain-of-function variant in GLS encoding GLS associated with profound developmental delay and infantile
cataract
. Functional analysis demonstrated that this variant causes hyperactivity and compensatory downregulation of GLS expression combined with upregulation of the counteracting enzyme GS, supporting pathogenicity. Ser482Cys-GLS likely improves the electrostatic environment of the GLS catalytic site, thereby intrinsically inducing hyperactivity. Alignment of +/-12.000 GLS protein sequences from >1000 genera revealed extreme conservation of Ser482 to the same degree as catalytic residues. Together with the hyperactivity, this indicates that Ser482 is evolutionarily preserved to achieve optimal-but submaximal-GLS activity. In line with GLS hyperactivity, increased glutamate and decreased glutamine concentrations were measured in urine and fibroblasts. In the brain (both grey and white matter), glutamate was also extremely high and glutamine was almost undetectable, demonstrated with magnetic resonance spectroscopic imaging at clinical field strength and subsequently supported at ultra-high field strength. Considering the neurotoxicity of glutamate when present in excess, the strikingly high glutamate concentrations measured in the brain provide an explanation for the developmental delay.
Cataract
, a known consequence of oxidative stress, was evoked in zebrafish expressing the hypermorphic Ser482Cys-GLS and could be alleviated by inhibition of GLS. The capacity to detoxify reactive oxygen species was reduced upon Ser482Cys-GLS expression, providing an explanation for
cataract
formation. In conclusion, we describe an inborn error of glutamate metabolism caused by a GLS hyperactivity variant, illustrating the importance of balanced GLS activity.
...
PMID:GLS hyperactivity causes glutamate excess, infantile cataract and profound developmental delay. 3023 21